Impact of Mupirocin Decolonization on the Nasal Microbiome

Stopped early

Conditions studied: Nasal Colonization With Staph Aureus

In brief

The normal bacteria that inhabit the human nose, also known as the nasal microbiome, may serve as a host defense mechanism against colonization and infection by Staphylococcus aureus, including methicillin resistant S. aureus (MRSA). Mupirocin is a topical antibacterial agent that may be used to clear nasal colonization with S. aureus, and reduce risk of S. aureus infection. The impact of mupirocin on the normal nasal microbiome is not known. We hypothesize that the nasal microbiome is changed by mupirocin. Our study aims to define the nasal microbiome before and after decolonization therapy with mupirocin.

Key facts

Study ID

NCT02045329

Run by

VA Eastern Colorado Health Care System

People needed

1

Starts

2013-10-01

Expected to finish

2015-06-05

Last updated by the study team

2018-10-17

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

• Age < 18 years Pregnant women Prisoners Decisionally challenged subjects

Where it is running

• Veterans Affairs Eastern Colorado Healthcare System — Denver, Colorado, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.